Sora Park

About Sora Park

Sora Park focuses her practice on intellectual property and data-driven transactions for clients in the technology and life sciences sectors. Her experience includes assisting clients in drafting and negotiating agreements involving the research, development and commercialization of new technologies and products, complex collaborations, software licensing (including SaaS and associated service-level and support agreements), and manufacturing and supply relationships. Sora also provides support on the intellectual property aspects of public and private cross-border mergers and acquisitions and strategic investments.

Recent work

• Johnson & Johnson on its $13.1 billion pending acquisition of Shockwave Medical, Inc.
• AstraZeneca in its acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, worth up to $2.4 billion.
• AstraZeneca on its $1.1bn acquisition of Icosavax.
• Roivant Sciences on its $7.1bn sale of Telavant to Roche.
• Capsida Biotherapeutics on its strategic partnership with Kate Therapeutics to leverage Capsida’s expertise and adeno-associated virus manufacturing capabilities to enable Kate’s initial internal portfolio of muscle and heart disease programs.
• PhenomeX in its agreement to sell to Bruker Corporation.
• Novartis in its acquisition of DTx Pharma, a biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
• Novartis on its collaboration and license agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of a novel medicine for patients with certain cardiovascular diseases.
• Innovation team of a leading healthcare provider on strategic technology and IP investments and transactions, including transactions involving novel SaMD, AI/ML and data analytic tools to improve healthcare delivery and outcomes.
• Capsida Biotherapeutics on its expanded strategic collaboration with AbbVie to develop genetic medicines for eye diseases, which includes $70 million upfront + equity and up to $595 million in option fees and R&D milestones with potential for future commercial milestones and royalties.
• Capsida Biotherapeutics on its CNS gene therapy collaboration with Prevail Therapeutics for $55 million (upfront + equity) and R&D milestones up to $685 million, as well as tiered royalties and a U.S. co-development/co-commercialization option in exchange for a gross margin share.
• Berkeley Lights (Nasdaq: BLI), a life sciences research tools company, on its acquisition of IsoPlexis (Nasdaq: ISO), a company empowering labs to leverage cells and the proteome, in an all-stock transaction valued at $57.8 million.
• Sairopa on its collaboration, option and license agreement with Exelixis to produce novel oncology therapies.
• Zymergen on its pending $300 million sale to Ginkgo Bioworks—the first-ever sale of a publicly-listed public benefit corporation.
• A patient access and experience-focused mental health company on the development of a digital ecosystem to facilitate patient access to mental healthcare.
• A leading provider of antimicrobial technology on its collaboration for the development and commercialization of antimicrobial products.
• Multiple digital health, medical device, bioengineering, medical technology, and biotechnology companies on their strategic technology and services contracts.
• Walker & Dunlop on the IP aspects of its $744 million acquisition of Alliant Capital, Ltd. and its affiliates, Alliant Strategic Investments and ADC Communities.
• Walker & Dunlop on advice regarding the IP aspects of its investments in technology companies.